摘要
目的探讨miR-22在儿童急性B淋巴细胞白血病(B-ALL)中的表达及临床意义。方法收集B-ALL患儿30例,以非恶性疾病或非血液病患儿10例为对照组。采集骨髓标本,提取RNA,实时荧光定量PCR方法检测miR-22的表达,并计算miR-22相对表达量。结果 miR-22相对表达量B-ALL患儿组显著低于对照组(P=0.001);治疗前显著低于治疗第33天及治疗第12周(P值分别为0.005和0.001);治疗第33天显著低于治疗第12周(P=0.012);10岁以上组显著低于10岁以下组(P=0.001);低危组显著高于中危组(P=0.007)及高危组(P=0.001);中危组与高危组比较差异无显著性(P=0.589)。结论 miR-22在儿童B-ALL中很可能存在抑癌作用。
Objective To investigate the expression and clinical significance of microRNA-22 （miR-22） in childhood B-cell acute lymphoblastic leukemia （B-ALL）. Methods Bone marrow samples were collected from 30 children with B-ALL and 10 children with nonhematologic malignancies. RT-PCR was performed to detect the expression levels of miR-22 in mononuclear cells. Results The relative expression levels of miR-22 in ALL samples were significantly lower than those in control group （P = 0. 001 ） ; the relative expression levels of miR-22 in newly diagnosed samples were lower than those in Day 33 and Week 12 samples respectively （P =0. 005 and P =0. 001 ） ; besides, the miR-22 expression levels in Day 33 samples were lower than those in week 12 samples （P =0. 012）. The relative expression levels of miR-22 in children with more than 10 years old were significantly lower than those in children under 10 years old （P =0. 001）. The miR-22 expression levels in low-risk group were higher than those in moderate-risk and high-risk groups respectively （P =0. 007 and P =0. 001 ）, and there was no difference between moderate-risk and high-risk groups （P = 0. 589 ）. Conclusions MiR-22 is likely to have anti-tumor effect in childhood B-ALL.
出处
《中国小儿血液与肿瘤杂志》
CAS
2012年第6期267-270,共4页
Journal of China Pediatric Blood and Cancer
